BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Innoviva Specialty Therapeutics inks distribution and licensing agreement with Dr. Reddyâ??s

17 June 2026 | News

Agreement expands access to XACDUROÂ® for patients with serious Acinetobacter baumannii-calcoaceticus complex infections



US-based Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., has entered into an exclusive distribution and licensing agreement with Hyderabad-based Dr. Reddy's Laboratories, for the development and commercialisation of XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use, in South and Central America, the Caribbean, Russia and Commonwealth of Independent States (CIS) countries.

In the United States, XACDURO® is approved and indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter).

Under the terms of the agreement, Dr. Reddy's will be responsible for development, regulatory and commercialisation activities in the licensed territory. Innoviva Specialty Therapeutics will retain rights to XACDURO in all unlicensed territories and is eligible to receive an upfront payment, regulatory and commercial milestone payments, and tiered royalties on net sales in the licensed territory.

Acinetobacter is a significant public health concern and is classified as a "critical threat" pathogen in World Health Organization global bacterial priority pathogens list.